• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Consumer Defensive·WVVI
Share

Willamette Valley Vineyards, Inc. Stocks

$ 2.51Last Updated 30.06.2026

Issuer Rating

3/7
Performance

Favourable

Risk

Considerable

Recommendation

Sell

Market Cap

$ 12.75M

$ 2.51
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Willamette Valley Vineyards, Inc. is a wine producer and vendor, distributing its products across both domestic U.S. and international markets. The company cultivates and vends an extensive array of wines under several distinct brands. Its flagship "Willamette Valley Vineyards" label showcases prominent varietals like Pinot Noir, Chardonnay, Pinot Gris, Pinot Blanc, Sauvignon Blanc, Gruner Veltliner, and Riesling, along with sparkling options including Rose, Brut, Brut Rose, and Blanc de Blancs. The "Tualatin Estate Vineyards" brand provides a Semi-Sparkling Muscat. Under the "Griffin Creek" marque, the portfolio expands to include Syrah, Merlot, Cabernet Sauvignon, Grenache, Cabernet Franc, Tempranillo, Malbec, Viognier, and their signature "The Griffin" blend. The "Oregon Cellars" label offers its unique Oregon Blossom. Furthermore, selections such as Pinot Noir and Chardonnay are found under the "Elton" label; Chrysologue, Merlot, and Cabernet Sauvignon under "Pambrun"; and a collection of Syrahs (Frontiere, Graviére, Voyageur), a Rose (Lisette), Grenache (Bourgeois), and Viognier (Voltigeur) are featured by "Maison Bleue." Additionally, specific wines are offered under the "Natoma" and "Metis" designations. The company manages roughly 1,018 acres of land through both ownership and leasing agreements. Marketing and sales efforts are conducted through multiple channels, including direct-to-consumer interactions at their winery and via mailing lists, in addition to wider distribution networks involving distributors and wine brokers. Established in 1983, Willamette Valley Vineyards, Inc. maintains its principal office in Turner, Oregon.

Company Valuation

Greatly undervalued
7/7

Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers. Specifically, the stock is undervalued on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

01.07.2026 20:33

"A Key Source of Value and Risk": Wall Street's Top Tech Optimist Assesses SpaceX

01.07.2026 19:21

Companies laid off employees because of artificial intelligence. Some came to regret it.

01.07.2026 18:59

Meta will launch a cloud infrastructure business. It will compete with Google and Nebius

01.07.2026 18:47

BlackRock is betting on scarce resources in AI supply chains. How should you build your portfolio?

01.07.2026 18:39

Shares of pharmaceutical company Galderma plummeted: The U.S. has halted sales of a Botox generic

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026